Despite the clear text, manufacturers frequently encounter issues with the Tacrolimus monograph:
The monograph defines Tacrolimus as a specific chemical entity, often referencing the hydrate form. One of the most crucial aspects of this section is the definition of potency. tacrolimus european pharmacopoeia monograph
This is a direct response to the risk of hypersensitivity reactions caused by trace host-cell proteins. Manufacturers must demonstrate validated clearance of biological impurities—a requirement less common in synthetic API monographs. : A batch compliant with Ph
Key regulatory implications:
Using the same HPLC method as for related substances (but with a different calculation algorithm), the assay confirms the 97.0–102.0% content. This range allows for the presence of the monohydrate form or slight manufacturing variance while ensuring therapeutic efficacy. Purity Tests and Impurity Profile
: A batch compliant with Ph. Eur. is not automatically USP-compliant. Separate validation is required for each market.
The retention time of the main peak in the chromatogram obtained with the test solution must be the same as the retention time of the main peak in the chromatogram obtained with the reference solution [2]. 4. Purity Tests and Impurity Profile